Provectus Biopharmaceuticals filings document governance, capital-structure actions, and material-event disclosures for a clinical-stage biotechnology issuer focused on rose bengal sodium-based medicines. Proxy materials cover annual-meeting voting matters, board elections, stock ownership, director and officer interests, and related-party transaction disclosures.
Form 8-K reports record corporate events such as annual-meeting announcements and amendments to the certificates of designation for Series D and Series D-1 Convertible Preferred Stock. These filings also describe preferred-stock conversion terms, common-stock implications, exhibit filings, and the company’s use of press releases to furnish updates tied to public-company reporting.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities related to prior financing arrangements. An 8% unsecured convertible promissory note converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 188,760 shares of common stock. Following these conversions, Pershing held 2,793,109 shares of common stock directly, with no remaining derivative position from this note.
Provectus Biopharmaceuticals, Inc. is asking stockholders to approve several key corporate and governance items at its 2026 annual meeting. The in‑person meeting is scheduled for June 18, 2026 in Knoxville, Tennessee, with a record date of April 20, 2026.
Stockholders will vote to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify CBIZ CPAs P.C. as independent auditor for 2026. The proxy details executive pay, including 2025 base salaries of $240,000 for the CEO and President and $200,000 for the CFO, plus prior large stock option grants under the 2024 Equity Compensation Plan.
The most structural proposals would authorize the board to implement a reverse stock split of common stock, Series D Preferred, and Series D‑1 Preferred at a ratio between 1‑for‑10 and 1‑for‑50, and, only if that split is approved, to proportionally reduce authorized common and preferred shares. As of the record date, there were 420,279,879 common shares outstanding, along with 956,985 Series D and 14,389,027 Series D‑1 shares. The board unanimously recommends voting “FOR” all five proposals.
Provectus Biopharmaceuticals CEO Edward Pershing reported a non-cash conversion of debt into equity. An 8% unsecured convertible promissory note automatically converted into 30,202 shares of Series D-1 Convertible Preferred Stock on April 29, 2026 at a conversion price of $2.862 per share.
Each Series D-1 preferred share is convertible into 10 shares of common stock, so the new preferred position represents 302,020 common shares. After this derivative exercise/conversion, Pershing directly owns 2,774,233 shares of Provectus common stock, with no remaining derivative position shown in this filing.
Provectus Biopharmaceuticals, Inc. is scheduling its 2026 Annual Meeting of Stockholders for June 18, 2026 at 4:00 p.m. Eastern Time at Perkins Place in Knoxville, Tennessee, which is planned to become the company’s new headquarters.
The company intends to relocate from its current offices at 800 S. Gay Street, Suite 1610, to Perkins Place in 2026. April 20, 2026 is the record date, and stockholders will receive a notice of internet availability with instructions to access the definitive proxy materials.
Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on rose bengal sodium, with programs in oncology, dermatology, ophthalmology, and several additional proof-of-concept areas.
Provectus Biopharmaceuticals, Inc. is soliciting proxies for its 2026 Annual Meeting to be held on June 18, 2026 where stockholders will vote on five proposals: election of four directors; an advisory vote on executive compensation; ratification of CBIZ as auditor; and two linked charter amendments to permit a reverse stock split (1-for-10 to 1-for-50) and a corresponding decrease in authorized shares if the split is implemented.
The proxy discloses governance, compensation and related-party financing details: 420,279,879 shares of common stock outstanding as of April 20, 2026, significant outstanding option awards (total 53,878,349 options exercisable at $0.29), a 2024 equity plan authorizing 100,000,000 shares, and related-party convertible note financings led by certain directors and a 5% stockholder.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported two non-market, derivative exercises. An 8% unsecured convertible promissory note, issued under the company’s 2025 financing, was converted into 33,977 shares of Series D-1 Convertible Preferred Stock at $2.862 per share. Each Series D-1 share is convertible into 10 common shares, and on the same date these preferred shares were converted into 339,770 shares of common stock. Following the conversion, Pershing directly owned 2,744,031 shares of common stock. The Series D-1 preferred would otherwise automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note that can be converted into 17,471 shares of Series D-1 Convertible Preferred Stock. The note may be voluntarily converted into Series D-1 Preferred at a price of $2.862 per share at any time while outstanding.
According to the disclosure, any outstanding principal and interest on the note will automatically convert into Series D-1 Preferred at the same $2.862 price per share twelve months after the note’s issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert to common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals, Inc. files its 2025 annual report outlining a broad rose bengal sodium (RBS)–based immunotherapy platform, spanning oncology, dermatology, ophthalmology and multiple early non-clinical programs. The company highlights an extensive U.S. and international patent estate supporting its pharmaceutical-grade RBS and PV‑10/PH‑10 candidates.
The report warns of substantial doubt about the company’s ability to continue as a going concern, citing an accumulated net loss of approximately $263 million since inception, a cash balance of $251,291 and a working capital deficit of $6,329,503 as of December 31, 2025. Management states that additional capital will be required in 2026 and beyond to advance clinical trials and operations.
As of June 30, 2025, the aggregate market value of common equity held by non‑affiliates was $30,585,685, based on a price of $0.075 per share. There were 420,279,879 shares of common stock outstanding as of March 23, 2026. The company also discloses cybersecurity, environmental and human‑capital practices, including a six‑person full‑time workforce and use of cloud‑based, third‑party monitored IT systems.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.